MedTrace Logo

Comparison of a Compound With Pilocarpine and Brimonidine to Improve Near Vision in Healthy Presbyopic Patients

NCT05001243 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2021-08-19

No results posted yet for this study

Summary

Safety and Efficacy of Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac (PBOHB) ophthalmic compound compared to Pilocarpine and Brimonidine to improve uncorrected near vision in healthy presbyopic patients one hour after instillation.

Conditions

Interventions

DRUG

Compound Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac

PBOHB to improve uncorrected near vision in healthy presbyopic patients

DRUG

Pilocarpine Hydrochloride

Apply in the fellow eye

DRUG

Brimonidine Tartrate

Apply in the fellow eye

Sponsors & Collaborators

  • Optall Vision

    lead OTHER

Principal Investigators

  • Cesar Alejandro S Galeana, MD · Optall Vision

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-10
Primary Completion
2021-08-30
Completion
2021-09-10

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05001243 on ClinicalTrials.gov